| Literature DB >> 16772030 |
Beverley Shea1, Maarten Boers, Jeremy M Grimshaw, Candyce Hamel, Lex M Bouter.
Abstract
BACKGROUND: Systematic reviews (SRs) must be of high quality. The purpose of our research was to compare the methodological and reporting quality of original versus updated Cochrane SRs to determine whether updating had improved these two quality dimensions.Entities:
Mesh:
Year: 2006 PMID: 16772030 PMCID: PMC1569863 DOI: 10.1186/1471-2288-6-27
Source DB: PubMed Journal: BMC Med Res Methodol ISSN: 1471-2288 Impact factor: 4.615
Comparisons of percent 'yes' and percent 'differences' using the enhanced Overview Quality Assessment Questionnaire (OQAQ).
| 1. Were the search methods used to find evidence reported? | 81% [68.9 to 93.4] | 87% [75.7 to 97.9] | 5.7% [-6.6 to 17.9] 0.43 |
| 2. Was the search strategy for evidence reasonably comprehensive? | 68% [47.0 to 88.7] | 70% [48.3 to 91.3] | 1.9% [-19.0 to 22.8] 0.83 |
| 3. Were the criteria used for deciding which studies to include in the overview reported? | 98% [94.4 to 100.0] | 91% [80.5 to 100.0] | -7.6% [-11.2 to 3.9] 0.09 |
| 4. Was bias in the selection of studies avoided? | 64% [45.4 to 82.8] | 70% [52.0 to 87.6] | 5.7% [-13.1 to 24.4] 0.53 |
| 5. Were criteria used for assessing validity of the included studies reported? | 89% [73.7 to 100.0] | 96% [85.9 to 100.0] | 7.6% [-7.4 to 22.5] 0.14 |
| 6. Was the validity of all studies referred to in the text assessed using appropriate criteria (either in selecting studies for inclusion or in analyzing studies that are cited)? | 85% [70.6 to 99.2] | 93% [82.9 to 100.0] | 7.6% [-0.68 to 21.9] 0.22 |
| 7. Were methods used to combine the findings of relevant studies (to reach a conclusion) reported? | 89% [66.2 to 99.8] | 83% [71.5 to 100.0] | -5.7% [-022.9 to 11.6] 0.40 |
| 8. Were findings of the relevant studies combined appropriately relative to the primary question addressed? | 87% [68.4 to 100.0] | 91% [78.7 to 100.0] | 3.8% [-14.6 to 22.2] 0.54 |
| 9. Were the conclusions made by the author (s) supported by the data and/or analysis reported in the overview? | 76% [63.8 to 87.2] | 94% [88.1–100.0] | 18.9% [7.2 to 30.6] 0.01 |
| 10. How would you rate the scientific quality of this overview? | 4.70 [4.47 to 4.94] | 4.81 [4.59 to 5.04] | 0.11 [-.28 to .70] 0.52 |
Comparisons of percent 'yes' and percent 'differences' using the Quality of Reporting of Meta-analyses (QUOROM).
| Identified the report as a meta-analysis [or systematic review] of randomized trials. | 0, 0% | 0, 0% | 0% NS | |||
| Used a structured format. | 100% | 100% | 0% NS | |||
| The clinical question explicitly. | 96.2% [91.0 to 100.0] | 98% [94.4 to 100.0] | 1.9% [-1.8 to 7.0] 0.56 | |||
| The databases (e.g. list) and other information sources. | 76% [63.8 to 87.2] | 93% [85.3 to 99.6] | 17.0% [9.8 to 28.7] 0.01 | |||
| The selection criteria (e.g. population, intervention, outcome, and study design; methods for validity assessment, data abstraction, and study characteristics, and quantitative data synthesis) in sufficient detail to permit replication. | 40% [26.3 to 52.9] | 76% [63.8 to 87.2] | 35.9% [24.1 to 49.1] 0.00 | |||
| Characteristics of the randomized trials included and excluded; qualitative and quantitative findings (e.g. point estimates and confidence intervals); and subgroup analyses. | 71% [59.5 to 83.9] | 77% [66.0 to 88.7] | 5.7% [-5.7 to 17.9] 0.50 | |||
| The main results. | 96% [91.4 to 100.0] | 98% [94.4 to 100.0] | 1.9% [-1.8 to 7.1] 0.56 | |||
| The explicit clinical problem, biologic rationale for the intervention, and rationale for review. | 98% [94.4 to 100.0] | 100% | 2% [1.9 to 5.6] 0.31 | |||
| The information sources, in detail (e.g., databases, registers, personal files, expert informants, agencies, hand-searching], and any restrictions (e.g. years considered, publication status, language of publication). | 68% [55.2 to 80.6] | 87% [77.7 to 96.0] | 18.9% [9.7 to 31.6] 0.02 | |||
| The inclusion and exclusion criteria (defining population, intervention principal outcomes, and study design). | 100% | 96% [91.0 to 100.0] | -3.7% [-9.0 to 3.8] 0.15 | |||
| The criteria and process used [e.g., masked conditions, quality assessment and their findings. | 87% [77.6 to 96.0] | 96% [91.0 to 100.0] | 9.4% [4.3 to 18.6] 0.08 | |||
| The process used (e.g., completed independently, in duplicate). | 74% [61.6 to 85.6] | 93% [85.3 to 99.6] | 18.9% [11.7 to 30.9] 0.01 | |||
| The type of study design, participants' characteristics, details of intervention, outcome definitions, etc.; and how clinical heterogeneity was assessed. | 89% [61.6 to 85.6] | 96% [91.0 to 100.0] | 7.6% [2.4 to 16.1] 0.14 | |||
| The principal measures of effect [e.g., relative risk], method of combining results (statistical testing and confidence intervals), handling of missing data, etc.; how statistical heterogeneity was assessed; a rationale for any a priori sensitivity and subgroup analyses; and any assessment of publication bias. | 83% [72.8 to 93.2] | 79% [68.2 to 90.2] | -3.7% [-14.8 to 6.4] 0.62 | |||
| Provide a meta-analysis profile summarizing trial flow | 2% [-1.8 to 5.6] | 8% [0.36 to 14.7] | 5.7% [-1.5 to 9.4] 0.17 | |||
| Present descriptive data for each trial [e.g., age, sample size, intervention, dose, and duration, follow-up]. | 89% [80.1 to 97.3] | 83% [72.9 to 93.2] | -5.7% [-15.9 to 2.9] 0.40 | |||
| Report agreement on the selection and validity assessment; present simple summary results [for each treatment group in each trial, for each primary outcome]; data needed to calculate effect sizes and confidence intervals in intention-to-treat analyses [e.g., 2 × 2 tables of counts, means and standard deviations, proportions]. | 81% [70.5 to 91.8] | 89% [80.1 to 97.3] | 7.5 [-1.1 to 18.2] 0.28 | |||
| Summarize the key findings; discuss clinical inferences based on internal and external validity; interpret the results in light of the totality of available evidence; describe potential biases in the review process [e.g., publication bias]; and suggest a future research agenda. | 96% [91.0 to 100.0] | 96% [91.0 to 100.0] | 0% [-5.2 to 5.2] NS | |||